Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TET1 small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
TET1 small interfering RNA (TET1 siRNA) is a double-stranded RNA molecule designed to target and silence the expression of the ten-eleven translocation 1 (TET1) gene. TET1 is a methylcytosine dioxygenase that catalyzes the conversion of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), playing a critical role in DNA demethylation and epigenetic regulation. In preclinical research, TET1 siRNA is utilized to investigate the role of DNA hydroxymethylation in various physiological and pathological processes, including synaptic plasticity, memory formation, epileptogenesis, and oncogenesis. For instance, studies in animal models of temporal lobe epilepsy have demonstrated that knockdown of TET1 in the hippocampus reduces 5-hmC levels and lowers the seizure threshold, suggesting that manipulating TET1 expression has therapeutic implications for epilepsy.
- Other names
- TET1 siRNATET-1 siRNATET 1 siRNAten-eleven translocation 1 small interfering RNA
02
Targets
TET1 (Methylcytosine dioxygenase TET1)
Beyond the preview
Go deeper on TET1 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TET1 small interfering RNA.